Compare BOF & CCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BOF | CCEL |
|---|---|---|
| Founded | 2017 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Managed Health Care |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.2M | 32.7M |
| IPO Year | 2023 | 1997 |
| Metric | BOF | CCEL |
|---|---|---|
| Price | $3.35 | $3.50 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 58.7K | 4.3K |
| Earning Date | 11-12-2025 | 10-15-2025 |
| Dividend Yield | N/A | ★ 11.43% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $11,218,127.00 | ★ $31,747,500.00 |
| Revenue This Year | N/A | $0.30 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 72.85 | N/A |
| 52 Week Low | $1.53 | $3.45 |
| 52 Week High | $3.66 | $8.79 |
| Indicator | BOF | CCEL |
|---|---|---|
| Relative Strength Index (RSI) | 53.09 | 38.36 |
| Support Level | $3.37 | $3.58 |
| Resistance Level | $3.66 | $3.99 |
| Average True Range (ATR) | 0.25 | 0.30 |
| MACD | -0.01 | -0.04 |
| Stochastic Oscillator | 38.74 | 3.90 |
Branchout Food inc is engaged in the development, marketing, sale, and distribution of plant-based, dehydrated fruit and vegetable snacks and powders. Its products are currently manufactured for the company by contract manufacturers based in South America and North America that produce dehydrated fruit and vegetable products for the company using a new proprietary dehydration technology that it licenses from a third party. The Company's customers are located throughout the United States. Its current primary products are BranchOut Snacks, BranchOut Powders, and BranchOut Industrial Ingredients.
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The Public cord blood banking segment consists of cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.